Velocity BioGroup Revenue and Competitors
Estimated Revenue & Valuation
- Velocity BioGroup's estimated annual revenue is currently $4M per year.
- Velocity BioGroup's estimated revenue per employee is $155,000
Employee Data
- Velocity BioGroup has 26 Employees.
- Velocity BioGroup grew their employee count by 0% last year.
Velocity BioGroup's People
Name | Title | Email/Phone |
---|
Velocity BioGroup Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5.4M | 35 | 483% | $25M | N/A |
#2 | $2M | 13 | 18% | N/A | N/A |
#3 | $3.4M | 22 | 10% | N/A | N/A |
#4 | $68M | 439 | -3% | N/A | N/A |
#5 | $2M | 13 | 30% | N/A | N/A |
#6 | $4M | 26 | 8% | N/A | N/A |
#7 | $2.7M | 35 | -10% | $23.2M | N/A |
#8 | $5.3M | 34 | 70% | N/A | N/A |
#9 | $1.7M | 11 | -8% | N/A | N/A |
#10 | $3.1M | 20 | -17% | N/A | N/A |
What Is Velocity BioGroup?
If the government pays, the feds usually have a role in it. What that means for you is that laws and regulations, centralized decision-making and cost-driven access constraints all play a critical role in market access. We know our way around Federal Markets to ensure that you will too. Velocity BioGroup is a strategic group of long-time business executives in the pharmaceutical, biologics, medical devices and Federal Markets, with very high-level relationships in the commercial and government payer world, public relations and advocacy communities. The primary function of the Velocity BioGroup team is to support your organization in framing a compelling formula for the success of your key products introduced in the market.
keywords:N/AN/A
Total Funding
26
Number of Employees
$4M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $3.2M | 26 | -16% | $12.5M |
#2 | $2.6M | 26 | N/A | N/A |
#3 | $2.6M | 26 | -21% | N/A |
#4 | $3.5M | 26 | 4% | N/A |
#5 | $2.4M | 26 | -7% | N/A |